Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akero Therapeutics Inc

Journey Medical Corp

Moderna

On Dec. 17, GuruFocus reported that in a July article, Kiplinger identified Morphic Holding Inc.

4 More Biotechs With Blockbuster Potential

Syros Pharmaceuticals

Global Blood Therapeutics Inc.  and Syros Pharmaceuticals announced a partnership to develop and commercialize therapies for sickle cell disease and beta thalassemia.

Global Blood Therapeutics and Syros Pharmaceuticals partner for sickle cell therapies

Balance Sheet Strengthened to Support Pipeline Advancement and Oxbryta™ (voxelotor) Commercialization

GBT Secures $150 Million Non-Dilutive Term Loan Financing

Collaboration Combines GBT’s Therapeutic Area Leadership with Power of Syros’  Gene Control Platform to Find New Medicines to Induce Fetal Hemoglobin

GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

Why Is Global Blood (GBT) Up 68.2% Since Last Earnings Report?

Allergan

Alector Inc

Amarin Corporation Plc

Athenex

Biohaven Pharmaceutical Hld

Cara Therapeutics

Intra-Cellular Therapies

Novartis

Puma Biotechnology

Protagonist Therapeutics

Proteostasis Therapeutics

Rocket Pharma

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Biotech’s Year-End To-Do List

SOUTH SAN FRANCISCO, Calif., Dec.  04, 2019  (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on December 1, 2019, the compensation committee of GBT’s board of directors granted 21 new employees options to purchase an aggregate of 13,000 shares of the company’s common stock with a per share exercise price of $66.50 and restricted stock units for an aggregate of 58,875 shares of the company’s common stock. All of the above-described awards were made under the GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). Pursuant to the Plan, the exercise price for the 13,000 shares of the Company’s common stock was the closing trading price on November 29, 2019, because there was no closing trading price on December 1, 2019.

GBT  - Announces  New Employment Inducement Grants

Global Blood Therapeutics: Oxbryta Is Aimed For Success

Global Blood (GBT) shares rose more than 5% in the last trading session, amid huge volumes.

Global Blood (GBT) in Focus: Stock Moves 5.2% Higher

Alnylam Pharmaceuticals

BeiGene

Vertex Pharmaceuticals

Here's why the FDA recently approved five new drugs way ahead of schedule.

5 New Drug Approvals the FDA Gave Top Priority

ARK Genomic Revolution Multi-Sector ETF

CRISPR Therapeutics

iShares Nasdaq Biotechnology ETF

Tesla

SPDR Gold Trust

Why Gold is Headed to Zero -- And What You Should Buy Instead

GBT, with a strong cash balance and low price, looks like it still has upside.

Global Blood Therapeutics: Oxbryta Is Finally Approved

Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.

Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD

VanEck Vectors Biotech ETF

First Trust NYSE Arca Biotechnology Index Fund

SPDR S&P Biotech ETF

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.

Why Biotech ETFs Surged in Monday's Trading Session

Global Blood Therapeutics: FDA Approval Of Oxbryta Moves Company Into A Large Market Opportunity

Global Blood Therapeutics, Inc. (NASDAQ: GBT) shares jumped on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older.

Why This Newly FDA Approved Sickle Cell Treatment Will Be Huge

GBT stock briefly broke out Tuesday after Global Blood Therapeutics gained earlier-than-expected approval of a sickle cell treatment.

This Biotech Broke Out Bullishly — But Couldn't Hold Onto That Gain

Shares of Global Blood Therapeutics GBT, +6.79% jumped 11% in premarket trading following the announcement Monday evening that the Food and Drug Administration had approved Oxbryta, its sickle cell disease treatment.

Global Blood Therapeutics stock is up on sickle cell therapy approval

First and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy

FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease

Transformative new therapies are changing the treatment landscape for patients with sickle cell disease, and savvy investors can benefit in this David-versus-Goliath scenario. Which one is the better buy today?

Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell

Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.

Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus

Global Blood Therapeutics recently held an analyst & investor day, outlining the critical need in sickle cell disease and how their lead drug, Voxelotor, fills the script.

Global Blood Therapeutics: Expectations Swell As Voxelotor Marketization Nears

First of Several Post-hoc Analyses Planned Using HOPE Study Clinical Data

GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor

Shares have flat performance since my December 2018 update.

Global Blood Therapeutics: A Core Biotech Buy For Patient Investors

Immunomedics

Major binary events like late-stage clinical trial results or drug approvals offer high-risk, high-reward opportunities for those who can stomach the uncertainty.

News for Global Blood Therapeutics Stock (GBT)